Anlon Healthcare reported strong annual performance for FY26: Revenue grew to ₹171.97 Cr from ₹120.29 Cr in FY25, and Profit After Tax (PAT) increased to ₹29.09 Cr from ₹20.52 Cr.

APIs were the main driver, contributing 71.24% of FY26 revenue.

However, Q4FY26 saw a modest revenue rise to ₹50.89 Cr, but PAT declined to ₹11.07 Cr from ₹16.65 Cr YoY, with EPS also decreasing to ₹2.33 from ₹5.15. Strategic moves include acquiring Apiqo Organics (completed) and Bizotic Lifescience (SPA executed), expanding manufacturing to 1,400-1,600 MTPA.

This boosts backward integration and capacity.

The company is diversifying into Industrial & Fine Chemicals, alongside new ventures in battery recycling, electronics repair, and e-waste management.

Management targets ~30% revenue CAGR over the next three years, aiming for sustainable 25-30% EBITDA margins.

Plans include launching 7 new APIs and filing 3-5 DMFs in FY26-27.